Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leflunomide - sanofi-aventis

Drug Profile

Leflunomide - sanofi-aventis

Alternative Names: Arava; HWA 486; SU 101

Latest Information Update: 18 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Pfizer
  • Class Antineoplastics; Disease-modifying antirheumatics; Isoxazoles; Small molecules
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors; Dihydropteroate synthase inhibitors; Epidermal growth factor receptor antagonists; Immunosuppressants; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Psoriatic arthritis; Rheumatoid arthritis
  • Discontinued Anaplastic astrocytoma; Autoimmune disorders; Cytomegalovirus infections; Glioblastoma; Graft-versus-host disease; Hypersensitivity; Immune-mediated uveitis; Multiple sclerosis; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Psoriasis; Systemic lupus erythematosus; Transplant rejection

Most Recent Events

  • 03 Dec 2018 Chang Zheng-Cinkate Pharmaceutical Corporation terminates a phase II trial for the prevention of kidney Transplant rejection in the USA due to lack of recruitment (PO) (NCT01620268)
  • 24 Jun 2018 Biomarkers information updated
  • 01 Oct 2015 Generic equivalent available in USA for Rheumatoid arthritis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top